The characteristics of demographics and cardiac arrest and baseline information affecting PK of midazolam were collected in this study. Serum samples for analyzing the plasma concentration of MDZ and its metabolites were obtained immediately (baseline) and at 4, 8, 12, and 24 h after the discontinuation of MDZ infusion. All known MDZ metabolites were analyzed (see Supplementary Fig. S1 online). The sample preparation and methodology for concentration analysis are described in the Supplemental Methods, which are available online.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.